Siliq
Siliq ingredients
| Active ingredient | Strength |
|---|---|
| Brodalumab | 210 mg/1 |
What Siliq is used for
The FDA lists the approved uses on the official label (below). In the EU, brodalumab is approved as Kyntheum for:
Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Siliq
- Generic name
- Brodalumab
- Made by
- Bausch Health US LLC
- Forms
- Injection
- Given
- Subcutaneous
- Drug class
- Interleukin-17 Receptor A Antagonist
- FDA approval
- Biologic licence (BLA) BLA761032
- On the US market since
- 2017
Official information
- Siliq prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Brodalumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Siliq?
Siliq (Brodalumab) is a specialist medicine made by Bausch Health US LLC, approved by the US FDA.
What are the ingredients of Siliq?
Siliq contains Brodalumab (210 mg/1).
Is Siliq approved in Europe?
The same active substance is approved in the EU as Kyntheum.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA